Approval for a modification of the indications for the hepacoat on bx sonic balloon-expandable stent otw delivery system.  The device, as modified, is indicated for improving coronary luminal diameter in the following:  1) for treatment of patients with symptomatic ischemic heart disease due to discrete de novo or restenotic lesions (<=30 mm in length) in native coronary arteries with reference diameters ranging from 3.0 mm to 5.0 mm involving direct stenting or predilatation; and  2) for treatment of abrupt or threatened vessel closure in patients with failed interventional therapy in lesions (<=30 mm in length) with reference diameters in the range of 2.25 mm to 4.0 mm.  The 2.25 mm, 2.5 mm, and 2.75 mm diameters are solely indicated for use in patients with abrupt or threatened closure, and the 4.5 and 5.0 mm diameters are indicated solely for use in patients with symptomatic ischemic heart disease due to discrete de novo or restenotic lesions.